Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Macaya Douoguih"'
Autor:
David Ishola, Daniela Manno, Muhammed O Afolabi, Babajide Keshinro, Viki Bockstal, Baimba Rogers, Kwabena Owusu-Kyei, Alimamy Serry-Bangura, Ibrahim Swaray, Brett Lowe, Dickens Kowuor, Frank Baiden, Thomas Mooney, Elizabeth Smout, Brian Köhn, Godfrey T Otieno, Morrison Jusu, Julie Foster, Mohamed Samai, Gibrilla Fadlu Deen, Heidi Larson, Shelley Lees, Neil Goldstein, Katherine E Gallagher, Auguste Gaddah, Dirk Heerwegh, Benoit Callendret, Kerstin Luhn, Cynthia Robinson, Maarten Leyssen, Brian Greenwood, Macaya Douoguih, Bailah Leigh, Deborah Watson-Jones, M Kargbo, E Bockarie, N L James, A Kabbah, A Kamara, K H Koroma, S O Langley, N William, R Kessebeh, T Mooney, L Conteh, E Smout, K Allieu, K Bangura, M S Bangura, M A Bangura, H Jalloh, A B Jalloh, I Kamara, M Kamara, A Konteh, S Koroma, C Marrah, M Sesay, M T Sesay, A T Deen, A Jalloh, R M Kaimbay, D Kain, E L Kamara, M P Kamara, O J Kamara, S L M Kamara, M Kanneh, A H Koroma, D Lahai, I S Mansaray, W S Marah, M J Massaquoi, A Nabie, N S Saidu, I Samai, J N Tengheh, A S Turay, A Fornah, F Sesay, A Sow, E Swaray, F Mansaray, T Ade-Cole, L M Bangura, M L Conteh, A M Koroma, M Koroma, A Sam, T Scott, T Sessie, J-H C Sunders, S I-S Turay, J Weekes, M Sheku, L Gibson, D Kowuor, I Ahamed, W Allieu, D U Kabba, F J Kamara, M S Kebbie, M Pessima, A Wurie, F Bah, A I Bangura, R A S Bangura, L Blango, S Boima, M Conteh, Y Conteh, M L Daramy, O Fofanah, E George, T F Hanson, M I Jalloh, M Kalawa, A M Kamara, F E Kamara, G M Kamara, H M Kamara, P B D Kamara, R T Kamara, R Kamara, D P Kanneh, I Komeh, M Kuyateh, F F Mansaray, M M Mansaray, A B Sillah, M A Tarawally, O S Turya, J B Yawmah, B Leigh, D Watson-Jones, B Greenwood, M H Samai, G F Deen, D Marke, P Piot, P Smith, J Edmunds, S Lees, H Larson, H Weiss, P Wilson, C Maxwell, D Ishola, M Afolabi, F Baiden, P Akoo, K Owusu-Kyei, D Tindanbil, H Bower, J Stuart, O M Bah, B T Rogers, A Serry-Bangura, I B Swaray, A Bangura, I J David, D G M Davies, J A Kallon, A B Kamara, I F Kamara, M M Kamara, F E Morovia, F B Suma, F Thompson, M Murray, I Sesay, O Kakay, F Suma, J Foster, R Philips, D Manno, K Gallager, S Cox, N Howard, M Cesay, P Torrani, S Sharma, E Snowden, T Banks, T Harber, J Brown, K Howard, N Melton, S Malcolm, S Welsh, R Eggo, M Jendrossek, C Pearson, J Van Hoof, M Douoguih, K Offergelt, C Robinson, B Keshinro, M Van Alst, N Mahajan, V Bockstal, N Goldstein, A Gaddah, D Heerwegh, K Luhn, M Leyssen, B Lowe, K Awuondo, H Hafezi, E Hancox, B Kohn, G O Tuda, F Koroma, G Bangura, M T Kroma, L Fofanah, A Pessima, M Rogers, O Sheriff, T W Ajala, J Fangawa, S Foday Jr, I Jabbie, B Mansaray, H A Mansaray, K Sesay, M K Charles, P C Heroe, M L Karbo, IS Yansaneh, S G Egoeh, A Trye, M Amponsah, N D Alghali, A Bah, IJ Bangura, A C Cole, K Fofanah, S Fofanah, H U Jalloh, K F N Jalloh, N Jalloh, H U Kabba, J N Kabba, M Kabba, J S Kamara, F Kanjie, A P Kanu, I Kargbo, G Kassa-Koroma, S B Koroma, A Sankoh, T Sankoh, O D Sesay, H Wilhem, C T Williams, I Bangura, Y Ben-Rogers, F J Jamboria, N Kamara, I Kanawah, A T Kargbo, I Swaray, L Amara, I Bundu, H B Jakema, K Kamara, M F Sheku, Q Adeleye, I Akhigbe, R Bakalemwa, N P Chami, T Sylvester, L Altmann, B Kamara, K van Roey, P Conteh, M Samura, V Gandie, M Marrah, E Moinina, J Kalokoh, M I Bangura, S Bosompem, T Hilton, M O Jusu, P Borboh, A S Brima, A F Y Caulker, A Kallon, B Koroma, RC Macauley, T M D Saquee, H I Williams, A R Bangura, J Fornah, B Idriss, M Sillah, W Mackay, B Aleghen, T Murray, J Edem-Hotah, T Fatorma, F Amara, S Bangura, E Bonnie, M Sannoh, A Donaldson, S Ndingi, D Nyaberi, M Pereira, A Rothwell, V Vy, L Nyallay, A Fombah, S Saidu, N Connor, T P Dambo, P J Fakaba, M M E Fatorma, C L Johnson, D B Kogba, A Lahai, W Vincent, N Yambasu, M Bangura, A Tengbeh, R Kabia, AM Nyakoi, M Callaghan, L Enria, S Lee
Publikováno v:
The Lancet Infectious Diseases. 22:97-109
Background: The Ebola epidemics in west Africa and the Democratic Republic of the Congo highlight an urgent need for safe and effective vaccines to prevent Ebola virus disease. We aimed to assess the safety and long-term immunogenicity of a two-dose
Autor:
Roland Zahn, Carlos Fierro, Maarten Leyssen, Marrit N. Habets, Kayvon Modjarrad, Rafael A. Larocca, Carla Truyers, Hanneke Schuitemaker, Leslie van der Fits, Diane G. Kanjilal, Kristi Lynn Williams, Nadine C. Salisch, Jenny Hendriks, Kathryn E. Stephenson, Macaya Douoguih, Johan Van Hoof, Dan H. Barouch, Conor P. Cahill, Freek Cox, Dirk Heerwegh, Jinyan Liu, Peter Abbink, Lauren Peter, Rafael De La Barrera
Publikováno v:
Annals of Internal Medicine. 174:585-594
BACKGROUND: Zika virus (ZIKV) may cause severe congenital disease after maternal-fetal transmission. No vaccine is currently available. OBJECTIVE: To assess the safety and immunogenicity of Ad26.ZIKV.001, a prophylactic ZIKV vaccine candidate. DESIGN
Autor:
Hilary S. Whitworth, Pontiano Kaleebu, George PrayGod, Macaya Douoguih, Saidi Kapiga, Deborah Watson-Jones, Dickson Anumendem, Kerstin Luhn, Samuel E. Kalluvya, Cynthia Robinson, Georgi Shukarev, Daniela Manno, Viki Bockstal, Zacchaeus Anywaine, Heiner Grosskurth
Publikováno v:
The Journal of Infectious Diseases
Background Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccina
Autor:
Andrew J Pollard, Odile Launay, Jean-Daniel Lelievre, Christine Lacabaratz, Sophie Grande, Neil Goldstein, Cynthia Robinson, Auguste Gaddah, Viki Bockstal, Aurelie Wiedemann, Maarten Leyssen, Kerstin Luhn, Laura Richert, Christine Bétard, Malick M Gibani, Elizabeth A Clutterbuck, Matthew D Snape, Yves Levy, Macaya Douoguih, Rodolphe Thiebaut, Christopher McShane, Benoit Callendret, Stephanie Dincq, Camille Ferrault, Siew Pin Chai, Maire Paule Gyselen, Marleen van Looveren, Sylvia van Ballert, Tinne de Cnodder, Len Roza, Chiara Forcheh, Kate Stevens, Carmela Mastrandrea, Sanne de Ridder, Rachana Gundluru, Nathalie Swales, Vanessa Errijegers, Wouter Willems, Veronika Roorda, Nicola Orzabal, Magdalena Assenberg, Karine Vialatte, Frédéric Remblier, Elodie Porcar, Anton Ottavi, Eugénie Destandau, Christine Schwimmer, Laetitia Moinot, Cédrick Wallet, Florence Allais, Hélène Savel, Naouel Nedjaai, Anaïs Maugard, Nehza Lenzi, Pierre Loulergue, Mathilde Bahuaud, Fabrice Lainé, Bruno Laviolle, Nolwenn Boissel, Elise Thébault, David Vallée, Jean-François Nicolas, Sophie Gilbert, Karima Dahel, Karen Sagorny, Frédéric Lucht, Stéphane Paul, Alice Haccourt Chanavat, Florent Charra, Catherine Mutter, Monique Lambour, Caroline Muller, Anne Hutt-Clauss, Olivia Aranda, Louis Bernard, Valérie Gissot, Marie-Charlotte Hallouin-Bernard, Alain Goudeau, Steve Suzzoni, Eva Auostin, Lysiane Brick, Jose-Luis Lopez-Zaragoza, Giovanna Melic, Murial Carvalho, Chrystel Chesnel, Hakim Hocini, Aurélie Wiedemann, Laurent Hanot, Véronique Rieux, Adeep Puri, Temitope Adeloye, Malcolm Boyce, Jeremy Dennison, Inge Loewenstein, Omar Sahgal, Frans van den Berg, Wendy Calvert, Mary Faldon, Bruce McClain, Marie-Lousie Newell, Geert Molenberghs
Publikováno v:
The Lancet Infectious Diseases
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2020, ⟨10.1016/S1473-3099(20)30476-X⟩
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2020, ⟨10.1016/S1473-3099(20)30476-X⟩
Summary Background To address the unmet medical need for an effective prophylactic vaccine against Ebola virus we assessed the safety and immunogenicity of three different two-dose heterologous vaccination regimens with a replication-deficient adenov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43c24659b62a3ec06bc9708186876d5
http://hdl.handle.net/20.500.12278/26684
http://hdl.handle.net/20.500.12278/26684
Autor:
Sarah Tete, Anna Marit de Groot, Carla Truyers, Jeroen N Stoop, Pierre Van Damme, Wim Van Damme, M. Juliana McElrath, Isabel Leroux-Roels, Mathieu Le Gars, Georgi Shukarev, Pieter-Jan Berghmans, Macaya Douoguih, Frank Struyf, Kristen W. Cohen, Emmanuel Cormier, Murray A Kimmel, Kathryn E. Stephenson, Dirk Heerwegh, Jerry Sadoff, Stephen C. De Rosa, Jan de Hoon, Gert Scheper, Johan Van Hoof, Jenny Hendriks, Dan H. Barouch, Hanneke Schuitemaker, William I. Smith
BACKGROUNDThe ongoing coronavirus disease (COVID)-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an efficacious vaccine. Multiple vaccines are in development, but no efficacious vaccine is cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dc5c432de05a2b06ee17c4d15799a77
https://doi.org/10.1101/2020.09.23.20199604
https://doi.org/10.1101/2020.09.23.20199604
Autor:
Kerstin Luhn, Dickson Anumendem, Gaudensia Mutua, Omu Anzala, Cynthia Robinson, Viki Bockstal, Macaya Douoguih
Publikováno v:
The Journal of Infectious Diseases
Background During the 2014 West African Ebola outbreak, Ebola vaccine development was accelerated. The phase 1 VAC52150EBL1003 study was performed to investigate 2-dose heterologous vaccination with Ad26.ZEBOV and MVA-BN-Filo in an African population
Autor:
Gavin J. Churchyard, Bernard Landry, Margaret A Snowden, Macaya Douoguih, J. Bruce McClain, Maria Grazia Pau, David A. Hokey, J. Sadoff, Veerabadran Dheenadhayalan
Publikováno v:
Vaccine. 33:1890-1896
Background The safety and immunogenicity of a replication deficient adenovirus serotype 35 tuberculosis (TB) vaccine containing gene inserts for Antigens (Ag) 85A, Ag85B and TB10.4 (AERAS-402/AD35.TB-S) was evaluated in previously BCG vaccinated, HIV
Autor:
Bruce McClain, Wendy Whatney, Angelique Luabeya Kany Kany, Jerald C. Sadoff, Nazma Mansoor, Hennie Geldenhuys, Marwou de Kock, Mark Hatherill, Maria Grazia Pau, Brian Abel, David A. Hokey, Jacqueline G. Benko, Colleen Krohn, Margaret A Snowden, Ashley Veldsman, Jenny Hendriks, Gregory D. Hussey, Hassan Mahomed, Thomas J. Scriba, Michele Tameris, Hadn Africa, Benjamin M. Kagina, Macaya Douoguih, Willem A. Hanekom, Jane Hughes
Publikováno v:
Vaccine. 32:5908-5917
Background Efforts to reduce risk of tuberculosis disease in children include development of effective vaccines. Our aim was to test safety and immunogenicity of the new adenovirus 35-vectored tuberculosis vaccine candidate AERAS-402 in infants, admi
Autor:
Mark Hatherill, Lewellys F. Barker, Jenny Hendriks, R. Walker, Videlis Nduba, V. Cardenas, Sadritdin Ishmukhamedov, Maria Pau, J. Sadoff, H. Geldenhuys, Katrina Downing, Veerabadran Dheenadhayalan, Jahit Sacarlal, Macaya Douoguih, Fatima Laher, David A. Hokey, Willem A. Hanekom, Barbara Shepherd, Sharon Nachman, G. Blatner, Angelique Kany Kany Luabeya, G. Kiringa, Glenda Gray, M. Tameris, Thomas J. Scriba, Hassan Mahomed, Brian Abel, J. B. McClain, K. Gondo, Erica Lazarus
Background Several novel tuberculosis vaccines are currently in clinical trials, including AERAS-402, an adenovector encoding a fusion protein of Mycobacterium tuberculosis antigens 85A, 85B, and TB10.4. A multicentred trial of AERAS-402 safety and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73367750c2152213f2fac5b1d6251721
https://europepmc.org/articles/PMC6698638/
https://europepmc.org/articles/PMC6698638/